Cancer Immunology and Immunotherapy Program

大卫·F·格罗恩和玛格丽特·T·格罗恩家族癌症免疫学和免疫治疗 计划项目摘要 癌症免疫学和免疫疗法(CII)计划是一门由来已久的基础科学和转化科学 梅奥诊所癌症中心(MCCC)内的项目。2016年，该项目正式获得了美国政府资助 大卫·F·格罗恩和玛格丽特·T·格罗恩家族。该计划将继续致力于更好地了解 免疫机制、炎症与癌症的关系及肿瘤的发展 通过免疫疗法抗击癌症的创新解决方案。CII计划做出了重大贡献 到检查站封锁疗法，这导致几个国家的护理标准发生了重大变化 不同的癌症。它现在准备做出更多的主要贡献，比如使用抗体靶向 化疗药物，有效针对黑色素瘤和卵巢癌，已被证明对 已有的治疗方法。该计划有35名成员，代表梅奥的14个不同部门 医学与科学临床学院。目前的成员是一支历史上生产力很高的团队，拥有 总发表论文超过5000篇，被引用超过245,000次。的主要目标是 该计划旨在提供一个互动、支持和持久的科学环境，以培养我们的四个 主要的前沿具体目标：(1)发展关于免疫系统如何运作的新知识， (2)开发以抗体为基础的治疗癌症的新疗法(3)识别和开发疫苗 可实施的预防癌症复发和提高免疫效果的方法 使用检查点抑制剂进行调制，以及(4)开发创新策略来重定向非肿瘤抗原- 特定的T细胞来攻击癌症。CII计划一直资金充足，目前得到支持 通过校外同行评审的赠款，总计360万美元的直接费用，其中约35%来自NCI。直接资助 来自非同行审查的赠款为840万美元，因此总额为1200万美元。这比去年同期增长了20% 最后一个资助期。在2013-2017年的时间框架内，计划成员发表了650份与癌症有关的出版物， 其中19%是方案内的，57%是方案间的，124个是在 影响系数≥10，反映工作质量并说明CII的高度互动 计划成员与其他MCCC计划的成员有联系。

DAVID F. AND MARGARET T. GROHNE FAMILY CANCER IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM PROJECT SUMMARY The Cancer Immunology and Immunotherapy (CII) Program is a longstanding basic and translational sciences program within the Mayo Clinic Cancer Center (MCCC). In 2016, this program was officially endowed by the David F. and Margaret T. Grohne Family. The Program continues to work toward better understanding the mechanisms of immunity, the relationship between inflammation and cancer, and the development of innovative solutions to combat cancer through immune therapy. The CII Program has contributed significantly to checkpoint blockade therapy, which has resulted in a major change in the standard of care of several different cancers. It is now poised to make additional major contributions such as using antibody-targeted chemotherapeutics, effectively targeting melanoma and ovarian cancers, which have proven nonresponsive to established therapies. The Program includes 35 members, representing 14 different departments in the Mayo Clinic College of Medicine and Science. The current membership is a historically highly productive team with a total publication record in excess of 5000 papers that has garnered over 245,000 citations. The main goal of the Program is to provide an interactive, supportive, and durable scientific environment to foster our four principal cutting-edge Specific Aims: (1) To develop new knowledge about how the immune system functions, (2) To develop novel antibody-based therapies for the treatment of cancers (3) To identify and develop vaccine approaches that can be implemented to protect against cancer recurrence and improve the efficacy of immune modulation with checkpoint inhibitors, and (4) To develop innovative strategies to redirect non-tumor antigen- specific T cells to attack cancer. The CII Program has been consistently well-funded and currently is supported by extramural peer-reviewed grants totaling $3.6M in direct costs of which ~35% are from NCI. Direct funding from non-peer-reviewed grants is $8.4M resulting in an overall total of $12M. This is a 20% increase over the last funding period. In the 2013-2017 timeframe, Program members published 650 cancer-related publications, of which 19% were intraprogrammatic, 57% were interprogrammatic, and 124 were published in journals with impact factors ≥10, reflecting the quality of the work and illustrating the high degree of interaction the CII Program members have with members of other MCCC Programs.